iMed Therapy

iMed Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative gene therapies for neurological and ophthalmic diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to design treatments that address high unmet medical needs, such as Amyotrophic Lateral Sclerosis (ALS). Headquartered in Shanghai, iMed Therapeutics focuses on optimizing vector delivery and expression to ensure safety and efficacy in complex central nervous system disorders. Their lead program, IMT-101, is currently advancing through early clinical trials. The company is backed by leading venture capital firms and aims to become a global leader in the field of genetic medicine.